| scholarly article | Q13442814 |
| P50 | author | Boris Freidlin | Q64496638 |
| P2093 | author name string | Edward L Korn | |
| P2860 | cites work | I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy | Q28244849 |
| A Multiple Testing Procedure for Clinical Trials | Q28248823 | ||
| Data monitoring committees and interim monitoring guidelines | Q30582009 | ||
| Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes | Q33408184 | ||
| A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome | Q33843955 | ||
| Randomized clinical trials with biomarkers: design issues | Q34024227 | ||
| The BATTLE trial: personalizing therapy for lung cancer | Q34275011 | ||
| Outcome--adaptive randomization: is it useful? | Q34667846 | ||
| Use of archived specimens in evaluation of prognostic and predictive biomarkers | Q35007222 | ||
| Using Randomization Tests to Preserve Type I Error With Response-Adaptive and Covariate-Adaptive Randomization | Q35108931 | ||
| Evaluating many treatments and biomarkers in oncology: a new design | Q35379179 | ||
| Design issues in randomized phase II/III trials | Q35808427 | ||
| Commentary on Hey and Kimmelman | Q35820701 | ||
| Randomized phase II trial designs with biomarkers | Q36212448 | ||
| Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. | Q36303134 | ||
| The Master Protocol Concept | Q36377768 | ||
| Bayesian clinical trials in action | Q36392556 | ||
| Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts | Q36593604 | ||
| Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial | Q36707077 | ||
| Multi-arm clinical trials of new agents: some design considerations | Q37217136 | ||
| Adaptive Randomization of Neratinib in Early Breast Cancer | Q37601709 | ||
| Marker Sequential Test (MaST) design | Q38148514 | ||
| Biomarker enrichment strategies: matching trial design to biomarker credentials | Q38166566 | ||
| Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials | Q39006058 | ||
| Comparison of futility monitoring guidelines using completed phase III oncology trials | Q39427133 | ||
| Are outcome-adaptive allocation trials ethical? | Q41677600 | ||
| The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer | Q42382909 | ||
| A general inefficacy interim monitoring rule for randomized clinical trials | Q45860572 | ||
| When is a seamless study desirable? Case studies from different pharmaceutical sponsors | Q50116411 | ||
| The likelihood as statistical evidence in multiple comparisons in clinical trials: no free lunch. | Q51937542 | ||
| An efficient design for phase III studies of combination chemotherapies. | Q52660911 | ||
| Discrete sequential boundaries for clinical trials | Q56780258 | ||
| Randomized clinical trials. Perspectives on some recent ideas | Q67482509 | ||
| Stopping when the experimental regimen does not appear to help | Q72838287 | ||
| Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients | Q81460457 | ||
| Rejoinder | Q86653348 | ||
| Commentary on Hey and Kimmelman | Q86653351 | ||
| Genomic Alteration-Driven Clinical Trial Designs in Oncology | Q89263763 | ||
| Molecular analysis for therapy choice: NCI MATCH | Q95433728 | ||
| Commentary on Hey and Kimmelman | Q95604155 | ||
| Commentary on Hey and Kimmelman | Q95604158 | ||
| Commentary on Hey and Kimmelman | Q95604163 | ||
| Commentary on Hey and Kimmelman | Q95604167 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2017-06-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. | |
| P478 | volume | 109 |
| Q89733229 | A review of available software for adaptive clinical trial design |
| Q52371842 | Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. |
| Q91757571 | Adaptive Signature Design- review of the biomarker guided adaptive phase -III controlled design |
| Q92640120 | Bayesian adaptive designs for multi-arm trials: an orthopaedic case study |
| Q61810177 | Clinical trial design and new therapies for pulmonary arterial hypertension |
| Q90342195 | Examining the Use of Real-World Evidence in the Regulatory Process |
| Q60444998 | Les essais cliniques en oncologie thoracique à l’ère de la médecine de précision : comment les réaliser en pratique ? |
| Q64113631 | New clinical trial designs in the era of precision medicine |
| Q56395253 | Overview of precision oncology trials: challenges and opportunities |
| Q91943657 | Phase II Trials in Drug Development and Adaptive Trial Design |
| Q101241316 | Preserving equipoise and performing randomized trials for COVID-19 social distancing interventions |
| Q92773280 | Process evaluation of a randomised controlled trial of PBS-based staff training for challenging behaviour in adults with intellectual disability |
| Q97646121 | Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness |
Search more.